Criticizes move to blanket-designate drugs as “medicines of concern for misuse or abuse”
Vows comprehensive review of rational management measures

The government’s plan to regulate obesity treatments such as Wegovy and Mounjaro by the same standards as erectile dysfunction drugs has come under fire. Park Yongjin, vice chair of the Regulatory Rationalization Committee, strongly criticized the Ministry of Food and Drug Safety’s (MFDS) blanket approach, saying it runs counter to global trends.

Former Democratic Party of Korea lawmaker Park Yongjin is interviewed at Parc.1 Tower in Yeouido, Seoul, on the 12th. Photo by Kang Jinhyung.

Former Democratic Party of Korea lawmaker Park Yongjin is interviewed at Parc.1 Tower in Yeouido, Seoul, on the 12th. Photo by Kang Jinhyung.

View original image

On October 11, Park said on social media, “We need to consider whether it is appropriate to view Viagra and Mounjaro within the same regulatory framework,” criticizing the MFDS for prioritizing administrative convenience. His remarks targeted the agency’s efforts to designate obesity treatments in the glucagon-like peptide-1 (GLP-1) class as so-called “medicines of concern for misuse or abuse” and impose strict controls on them. With the appropriateness of current measures already under debate, including restrictions on bringing the drugs through customs, Park argued that the effectiveness of any additional regulations should be reconsidered from the ground up.


He cited the fundamental shift in how the international community views obesity. Park noted that the World Health Organization defines obesity as a chronic disease with a high likelihood of relapse and has included related treatments on its list of essential medicines for certain high-risk groups. He said that while major developed countries are focusing on careful prescribing within the regulated healthcare system and cracking down on counterfeit distribution, rather than hastily categorizing obesity drugs as subject to misuse or abuse, South Korea is trying to put them in the same regulatory straitjacket as erectile dysfunction drugs and steroids.



Park said excessive restrictions are instead fueling harmful activity in the shadows. “If regulation only leaves people fearing and stigmatizing these drugs as dangerous, without actually reducing misuse or abuse, then it needs to be reconsidered,” he said. “If high prices and limited access are leading to overseas purchases, illegal distribution and people sharing doses, we need to address the underlying causes.” He added, “The Regulatory Rationalization Committee will take a comprehensive look at the basis for the MFDS designation, the potential impact of the regulations, management practices overseas, and concerns raised by patients and others on the ground, and will carefully reassess effective ways to manage these drugs within the regulated system.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing